Through the study, healthy volunteers will receive a dose of TD-0903, a lung-selective, nebulized Janus kinase inhibitor. The company is looking at the inhibitor as a way to treat patients hospitalized with acute lung injury due to the novel coronavirus. The molecule was developed for broad inhibition of the Janus kinase/signal transducer and activator of transcription (JAK-STAT) signaling pathway, the principal pathway for cytokines and growth factors, and therefore has the potential to prevent a cytokine storm during lung injury.

Phase I of the study will look at the safety, tolerability, and pharmacokinetics of various doses of TD-0903. If the study moves forward, phase II will evaluate the same regimen in patients hospitalized with COVID-19 in the U.K.

COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...

NIAID announces new COVID-19 priorities
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) has released a new strategic plan for accelerating research to diagnose, prevent,...

Does SARS-CoV-2 use host defenses to infect susceptible cells?
A new study pinpoints the most likely cell types that SARS-CoV-2 infects. Unexpectedly, the study indicates that one of the body's main defenses against...

Bioinformatics helps pinpoint evolutionary mutations of SARS-CoV-2
A new bioinformatics approach to classifying genetic variants of SARS-CoV-2 helps to answer questions such as whether there are one or more circulating...

Medable launches COVID-19 research collaboration
Medable has launched a research collaboration with five other organizations to develop diagnostics and treatment for COVID-19.